Methods of treatment using taci-immunoglobulin fusion proteins
AssigneeZymoGenetics, Inc.
InventorsMark W. Rixon, Jane A. Gross
Life of this patent
Estimating the term…
Abstract
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
Claims16
A method of treating systemic lupus erythematosus comprising administering to a mammalian subject in need thereof a composition comprising a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI)-immunoglobulin fusion protein, wherein the TACI-immunoglobulin fusion protein comprises:
- (a) a TACT receptor moiety that consists of:
- i) amino acid residues 30-110 of SEQ ID NO:2;
- or,
- ii) amino acid residues 30-154 of SEQ ID NO:2;
- wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4, and
- (b) an immunoglobulin moiety comprising a CH2 and CH3 domain.
A method of treating secondary glomerulonephritis associated with systemic lupus erythematosus comprising administering to a mammalian subject in need thereof a composition comprising a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI)-immunoglobulin fusion protein, wherein the TACI-immunoglobulin fusion protein comprises:
- (a) a TACT receptor moiety that consists of:
- i) amino acid residues 30-110 of SEQ ID NO:2;
- or,
- ii) amino acid residues 30-154 of SEQ ID NO:2;
- wherein the TACT receptor moiety binds at least one of ZTNF2 or ZTNF4, and
- (b) an immunoglobulin moiety comprising a CH2 and CH3 domain.
Dependencies are inferred from the claim text.